New pill targets KRAS cancers in early human trial

NCT ID NCT06835569

Recruiting now Disease control Sponsor: Alterome Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests an oral drug called ALTA3263 in about 448 adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a KRAS mutation. The main goals are to check safety, find the right dose, and see how the body processes the drug. Participants have already tried other treatments without success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ALTA3263 (oral tablet)

What this could lead to

If successful, this could point toward a new treatment option for people with advanced cancers that have KRAS mutations.

What could go wrong

This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. Many drugs fail in early testing, and side effects are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer carcinoma colonic neoplasm colorectal cancer colorectal carcinoma colorectal neoplasm lung neoplasm neoplasm Neoplasm Metastasis Neoplasms by Site non-small cell lung carcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS CANCER CRC (COLORECTAL CANCER) NSCLC (NON-SMALL CELL LUNG CANCER) PDAC - PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Orlando, Florida, 32827, United States
Research Site
RECRUITING

Boston, Massachusetts, 02114, United States
Research Site
RECRUITING

Boston, Massachusetts, 02115, United States
Research Site
RECRUITING

St Louis, Missouri, 63110, United States
Research Site
RECRUITING

New York, New York, 10016, United States
Research Site
RECRUITING

New York, New York, 10032, United States
Research Site
RECRUITING

Durham, North Carolina, 27710, United States
Research Site
RECRUITING

Nashville, Tennessee, 37203, United States
Research Site
RECRUITING

Houston, Texas, 77030, United States
Research Site
RECRUITING

San Antonio, Texas, 78229, United States
Research Site
RECRUITING

Fairfax, Virginia, 22031, United States
Research Site #2
RECRUITING

San Antonio, Texas, 78229, United States